Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
87 hedge funds and large institutions have $572M invested in Rubius Therapeutics, Inc in 2020 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 33 reducing their positions, and 8 closing their positions.
508% more call options, than puts
Call options by funds: $2.44M | Put options by funds: $402K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
50% more capital invested
Capital invested by funds: $382M → $572M (+$190M)
4% more funds holding
Funds holding: 84 → 87 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
21% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.83M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$2.59M |
| 3 |
JP Morgan Chase
New York
|
+$1.66M |
| 4 |
D.E. Shaw & Co
New York
|
+$735K |
| 5 |
HHAM
HITE Hedge Asset Management
Braintree,
Massachusetts
|
+$527K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$438K |
| 2 |
BlackRock
New York
|
-$242K |
| 3 |
Goldman Sachs
New York
|
-$232K |
| 4 |
HF
HRT Financial
New York
|
-$230K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$222K |
RUBY Hedge Fund Activity: Q4 2020 in Review
87 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q4 2020, worth a combined $572M — up 50% from $382M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RUBY positions and 8 closed out — a net gain of 4 holders — while 26 added to existing stakes and 33 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $6.83M. The largest seller was Renaissance Technologies, cutting an estimated $438K.
- 87 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q4 2020, up from 84 in Q3 2020.
- Funds reported $572M of Rubius Therapeutics, Inc stock for Q4 2020, up 50% quarter-over-quarter.
- 12 funds opened new Rubius Therapeutics, Inc positions in Q4 2020 and 8 closed out, a net change of +4 holders.
- The largest Rubius Therapeutics, Inc buyer in Q4 2020 was Fidelity Investments, an estimated $6.83M added.
- The largest Rubius Therapeutics, Inc seller in Q4 2020 was Renaissance Technologies, an estimated $438K sold.
Based on aggregated 13F filings for Q4 2020.